Persistence of Rabies Virus-Neutralizing Antibodies after Vaccination of Rural Population following Vampire Bat Rabies Outbreak in Brazil - PubMed (original) (raw)
. 2016 Sep 21;10(9):e0004920.
doi: 10.1371/journal.pntd.0004920. eCollection 2016 Sep.
Viviane Jusot 2, Guy Houillon 2, Anvar Rasuli 2, Luzia Martorelli 3, Ana Paula Kataoka 3, Mohamed Ben Mechlia 4, Anne-Sophie Le Guern 4, Liliam Rodrigues 1, Rhomero Assef 1, Alvino Maestri 1, Reynaldo Lima 5, Yolande Rotivel 4, Valérie Bosch-Castells 2, Noël Tordo 4 5 6
Affiliations
- PMID: 27653947
- PMCID: PMC5031405
- DOI: 10.1371/journal.pntd.0004920
Persistence of Rabies Virus-Neutralizing Antibodies after Vaccination of Rural Population following Vampire Bat Rabies Outbreak in Brazil
Rita Medeiros et al. PLoS Negl Trop Dis. 2016.
Abstract
Background: Animal control measures in Latin America have decreased the incidence of urban human rabies transmitted by dogs and cats; currently most cases of human rabies are transmitted by bats. In 2004-2005, rabies outbreaks in populations living in rural Brazil prompted widespread vaccination of exposed and at-risk populations. More than 3,500 inhabitants of Augusto Correa (Pará State) received either post-exposure (PEP) or pre-exposure (PrEP) prophylaxis. This study evaluated the persistence of rabies virus-neutralizing antibodies (RVNA) annually for 4 years post-vaccination. The aim was to evaluate the impact of rabies PrEP and PEP in a population at risk living in a rural setting to help improve management of vampire bat exposure and provide additional data on the need for booster vaccination against rabies.
Methodology/principal findings: This prospective study was conducted in 2007 through 2009 in a population previously vaccinated in 2005; study participants were followed-up annually. An RVNA titer >0.5 International Units (IU)/mL was chosen as the threshold of seroconversion. Participants with titers ≤0.5 IU/mL or Equivalent Units (EU)/mL at enrollment or at subsequent annual visits received booster doses of purified Vero cell rabies vaccine (PVRV). Adherence of the participants from this Amazonian community to the study protocol was excellent, with 428 of the 509 (84%) who attended the first interview in 2007 returning for the final visit in 2009. The long-term RVNA persistence was good, with 85-88.0% of the non-boosted participants evaluated at each yearly follow-up visit remaining seroconverted. Similar RVNA persistence profiles were observed in participants originally given PEP or PrEP in 2005, and the GMT of the study population remained >1 IU/mL 4 years after vaccination. At the end of the study, 51 subjects (11.9% of the interviewed population) had received at least one dose of booster since their vaccination in 2005.
Conclusions/significance: This study and the events preceding it underscore the need for the health authorities in rabies enzootic countries to decide on the best strategies and timing for the introduction of routine rabies PrEP vaccination in affected areas.
Conflict of interest statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: RM, LM, APK, MBM, ASLG, LR, RA, AM, RL, YR and NT have no conflicts of interest to declare. GH, AR and VBC are Sanofi Pasteur employees. VJ was a Sanofi Pasteur employee at the time of study conduct. This does not alter our adherence to all PLoS policies on sharing data and materials.
Figures
Similar articles
- Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
Pichon S, Moureau A, Petit C, Chu L, Essink B, Muse D, Saleh J, Guinet-Morlot F, Minutello AM. Pichon S, et al. Vaccine. 2022 Aug 5;40(33):4780-4787. doi: 10.1016/j.vaccine.2022.06.040. Epub 2022 Jun 28. Vaccine. 2022. PMID: 35778281 Clinical Trial. - Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
Quiambao BP, Ambas C, Diego S, Bosch Castells V, Korejwo J, Petit C, Rasuli A, Houillon G. Quiambao BP, et al. Vaccine. 2020 May 6;38(21):3740-3746. doi: 10.1016/j.vaccine.2020.03.043. Epub 2020 Apr 9. Vaccine. 2020. PMID: 32280042 Clinical Trial. - One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety.
Quiambao BP, Lim JG, Bosch Castells V, Augard C, Petit C, Bravo C, Delore V, Houillon G. Quiambao BP, et al. Vaccine. 2022 Aug 26;40(36):5347-5355. doi: 10.1016/j.vaccine.2022.07.037. Epub 2022 Aug 3. Vaccine. 2022. PMID: 35933278 Clinical Trial. - Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019.
Moulenat T, Petit C, Bosch Castells V, Houillon G. Moulenat T, et al. Trop Med Infect Dis. 2020 Mar 7;5(1):40. doi: 10.3390/tropicalmed5010040. Trop Med Infect Dis. 2020. PMID: 32156005 Free PMC article. Review. - Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: a systematic literature review and meta-analysis.
Preiss S, Chanthavanich P, Chen LH, Marano C, Buchy P, van Hoorn R, Vonk Noordegraaf M, Mukherjee P. Preiss S, et al. Expert Rev Vaccines. 2018 Jun;17(6):525-545. doi: 10.1080/14760584.2018.1473765. Epub 2018 Jun 25. Expert Rev Vaccines. 2018. PMID: 29939085 Review.
Cited by
- Pre-Exposure Prophylaxis to Prevent Hematophagous Bat-Mediated Rabies Outbreaks in Remote Amazon Communities: Lessons from a Pilot for Public Health Policy.
Rocha F, Vargas A, Abreu EMN, Pompei JCA, Vigilato MAN, Lima DM, Vianna RS, Cosivi O, Recuenco SE, Costa WA, Hardt L, Ferreira KCS, Neto RDSC, Chaves LB, Silva ACRD, Begot AL, Andrade JAA, Marcos W, Rocha SM, Junior FEFL, Wada MY. Rocha F, et al. Trop Med Infect Dis. 2024 Aug 14;9(8):179. doi: 10.3390/tropicalmed9080179. Trop Med Infect Dis. 2024. PMID: 39195617 Free PMC article. - Knowledge of rabies among rural community in Chengalpet district, India.
Bharani K, Ramachandran K, Kommisetty V, Baalann KP. Bharani K, et al. Bioinformation. 2022 Mar 31;18(3):155-159. doi: 10.6026/97320630018155. eCollection 2022. Bioinformation. 2022. PMID: 36518126 Free PMC article. - Evolution of Rabies in South America and Inter-Species Dynamics (2009-2018).
Meske M, Fanelli A, Rocha F, Awada L, Soto PC, Mapitse N, Tizzani P. Meske M, et al. Trop Med Infect Dis. 2021 Jun 9;6(2):98. doi: 10.3390/tropicalmed6020098. Trop Med Infect Dis. 2021. PMID: 34207822 Free PMC article. - Systematic Booster after Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure.
Parize P, Sommé J, Schaeffer L, Ribadeau-Dumas F, Benabdelkader S, Durand A, Tarantola A, Cailhol J, Goesch J, Kergoat L, Le Guern AS, Mousel ML, Dacheux L, Consigny PH, Fontanet A, Francuz B, Bourhy H. Parize P, et al. Vaccines (Basel). 2021 Mar 24;9(4):309. doi: 10.3390/vaccines9040309. Vaccines (Basel). 2021. PMID: 33805019 Free PMC article. - Jumping species-a mechanism for coronavirus persistence and survival.
Menachery VD, Graham RL, Baric RS. Menachery VD, et al. Curr Opin Virol. 2017 Apr;23:1-7. doi: 10.1016/j.coviro.2017.01.002. Epub 2017 Mar 31. Curr Opin Virol. 2017. PMID: 28214731 Free PMC article. Review.
References
- Dietzgen RG, Calisher CH, Kurath G, Kuzmin IV, Rogriguez LL, et al. (2011) Rhabdoviridae In: Virus taxonomy: classification and nomenclature of viruses: Ninth Report of the International Committee on Taxonomy of Viruses. Ed: King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. pp. 654–680. San Diego, Elsevier
- International Committee on Taxonomy of Viruses, Virus Taxonomy, 2014 release, http://ictvonline.org/virustaxonomy.asp
Grants and funding
The study sponsor and funder, Sanofi Pasteur, was involved in all stages of the study, including study design, data collection, analysis and interpretation, preparation of this article, and decision to submit the article for publication.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous